The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Tyke...
I don't think TB cares about the market reaction. I guess his mission was was to raise some £ to cover some costs (done) and steer the company around the FDA (done). Unlike Trek and some others I don't understand how TB et al benefitted from the recent fund-raise so there's not much I can say about that. My approach remains the same - buy some stock but not too much. If I could see more clearly what was going on I would buy more - but I don't understand this company so I don't invest 2 much.
I suspect this is a long term play - 2027 could be a year here if the company hasn't delisted or been bought out.
The creative/tech team here may well have a golden touch. The response from the FDA is amazing. This is good news. If that golden streak keeps on keeping on and we get similar progress with GE/Bayer and sales/contracts over the next 6 to 24 months this is going to be a very interesting stock.
selling for 10%? seems a shame when its this cheap and may well have a lot further to run.
20p in the old days? well back then most of AIM and some main market stocks were considerably over valued. all that tells me is that anyone getting in for sub 5p is way below everyone else's average. if you buy now only the CEO and whoever took that last placing is lower than you (I think), and then only by a sliver, an enviable position.
Phone your broker?
great. ask him/her about the fundraise (mentioned in the RNS) on the transfer of the company to AIM.
that's going to be the big one...surely? thats the one you want in on.
IMM about $20 million on their Phase 2
But...maybe IQAI have no intention of launching a Phase 2. The EAP is their stated objective. So an EAP in territory after territory will bring in some income? Make the drug attractive so someone else will pick it up? Or just give IB tremendous prestige - they will have managed to launch a successful drug, that is actually being used, to save lives, on a shoestring. That is quite something. And they are now besties with the FDA - who owe them a favor with the MRI biz.
Have IQAI given us any numbers on potential revenue? Just that $100 million figure on a PRV that can be sold/transferred - which perhaps that suggests they want the EAP up and running, perhaps globally, then see if they pull off a license deal - or, just let it sit as an EAP type drug? I don't know much about the latter situation, like can a drug be made available for years and years under EAP programs and never go to further trials?
Either way 2024 should be news rich and very interesting. And 2025....
Does this mean they can get revenue? Drs can prescribe it - presumably there is a cost. I have no idea how many patients are eligible or at what cost. Still, good news is good news. And obviously good news for the patients. And it must be one more sign that the medical science people at this company are really very good - lightning will strike again. And again.
Be. In. It.
Its out? I missed it?
I was on holiday in Bologna region - and didn't have great wifi for most of the time - an annual report came out and share price hasn't dropped 30 or 40 per cent? I am very much looking forwards to read it.
And having just got back I would heartily recommend a visit Bologna - its very exciting to walk around the endless arcades in the centre of the city and if you want some peace and quiet in the same region then Orvieto, Assisi and Ravenna are quiet, beautiful places. Anyway off to read the report and quite pleased the share price hasn't collapsed - which, to be honest, was what I imagined would happen.
Damn I should read the RNS's more carefully - so Martin notified re his wife's dealings - so sorry for suggesting that he might be an issue here. Sorry about that, its easy to miss the one most crucial sentence when your jaw is on the floor.
They need to reassure us that the founder of the company is not dishonest. I sold a few weeks ago and I am thinking of buying back in - BUT I would be concerned if the fonder/tech guy was dishonest - I wouldn't want to read that he faked research. But I guess that is very very unlikely.
TEK? Sorry to go off IMM.
They've just done their placing. Shares are churning. If they've churned then next bit of news or next bit of volume you might get a rise in the sp. No idea how much. If you are chasing 10% it might be there.
Accounts - I struggle with reading accounts. But also laziness (mine) doesn't help. Thanks for the responses. I will try and make a big effort to spend a bit more focused time on the accounts/results. I suspect there isn't a great deal of £ washing about. I hope I'm wrong.
They said they need a CPT code to help with sales. They haven't got it yet. We could get bumpy results...then...in May, the light...????
From a recent RNS...
CPT Code: "Earlier this year, we made the strategic decision to apply for a Current Procedure Terminology (CPT) code specific to the DSC perfusion technology available in IB Neuro. The application is due in early November and a final decision will be made in May 2024. A CPT code will help make for easier buying decisions for healthcare administrators."